Business Context and Reporting Period
This Form 8-K filing by Neoleukin Therapeutics, Inc. (NLTX) reports a corporate governance event dated February 25, 2020. The registrant is a Delaware corporation with principal executive offices in Seattle, Washington, and its common stock trades on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of Robert Ho as Chief Financial Officer (CFO), effective March 16, 2020. Concurrently, Kamran Alam, the Interim CFO and Vice President of Finance, will resign from those positions to serve as Senior Strategic Advisor.
Management Commentary and Compensation Details
The Board approved an employment agreement for Mr. Ho with the following terms:
- Base Salary: $350,000 annually.
- Bonus: Discretionary annual bonus up to 40% of base salary.
- Equity Awards:
- 75,000 Restricted Stock Units (RSUs) vesting in three equal annual installments.
- Option to purchase 200,000 shares, with 25% vesting after one year and the remainder vesting monthly thereafter.
- Severance Provisions:
- Standard termination without cause or resignation for good reason: 9 months of base salary and healthcare coverage.
- Termination within 12 months of a change in control: 12 months of base salary, 100% target bonus, 12 months of healthcare, and 100% accelerated vesting of equity.
Mr. Ho's background includes roles at DaVita Inc. and Morgan Stanley. The full Employment Agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2020.
Investor Verification Checklist
- Verify the effective date of Robert Ho's appointment (March 16, 2020) and Kamran Alam's transition to Senior Strategic Advisor.
- Review the full Employment Agreement upon its filing in the upcoming Form 10-Q for detailed definitions of "cause," "good reason," and "change in control."
- Monitor the impact of the new CFO's background in healthcare investment banking and dialysis services on the company's strategic direction.
- Confirm the vesting schedule and exercise terms for the 200,000 stock options granted.